VeriStrat (R) has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

Oliver Gautschi*, Anne-Marie Dingemans, Susanne Crowe, Solange Peters, Heinrich Roder, Julia Grigorieva, Joanna Roder, Francesco Zappa, Miklos Pless, Martin Brutsche, Florent Baty, Lukas Bubendorf, Shu-Fang Hsu Schmitz, Kyung-Jae Na, David Carbone, Rolf Stahel, Egbert Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

22 Citations (Web of Science)

Abstract

Background: VeriStrat (R) is a serum proteomic test used to determine whether patients with advanced non-small cell lung cancer (NSCLC) who have already received chemotherapy are likely to have good or poor outcomes from treatment with gefitinib or erlotinib. The main objective of our retrospective study was to evaluate the role of VS as a marker of overall survival (OS) in patients treated with erlotinib and bevacizumab in the first line. Patients and methods: Patients were pooled from two phase II trials (SAKK19/05 and NTR528). For survival analyses, a log-rank test was used to determine if there was a statistically significant difference between groups. The hazard ratio (HR) of any separation was assessed using Cox proportional hazards models. Results: 117 patients were analyzed. VeriStrat classified patients into two groups which had a statistically significant difference in duration of OS (p = 0.0027, HR = 0.480, 95% confidence interval: 0.294-0.784). Conclusion: VeriStrat has a prognostic role in patients with advanced, nonsquamous NSCLC treated with erlotinib and bevacizumab in the first line. Further work is needed to study the predictive role of VeriStrat for erlotinib and bevacizumab in chemotherapy-untreated patients.
Original languageEnglish
Pages (from-to)59-64
JournalLung Cancer
Volume79
Issue number1
DOIs
Publication statusPublished - Jan 2013

Keywords

  • Biomarker
  • Chemotherapy
  • EGFR inhibitor
  • Lung cancer
  • Personalized medicine
  • Proteomics

Cite this